Women’s health 2.0 has arrived.
What’s happening: Shifting from episodic to lifelong care, the category is projected to reach $600B globally by 2030, up from $430B today, per PwC.
Longitudinal care. Intersecting with life stages, the market is evolving beyond reproductive health and oncology to include conditions that affect women uniquely, disproportionately, and differently from men.
Broadening the core, menopause is growing 8–10% annually, while pelvic health, endometriosis, and PCOS emerge as growth areas. Meanwhile, adjacent conditions are being reexamined for female bodies — with women comprising two-thirds of neurodegenerative and 80% of autoimmune patients, each category will jump ~10% YoY.
Growth mode. Since 2020, women’s health companies have raised ~$60B in capital across 2K+ deals. Building on fertility and pregnancy, women’s oncology, menopause, and gender-specific diagnostics and treatments are active investment areas — specifically across virtual care, at-home testing, and AI analysis.
Punchline: No longer niche, women’s health is reaching an inflection point. But, accounting for only 5% of overall healthcare R&D, the category requires innovation, data, and cash flow to scale integrated, lifelong care for half the world.
